FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

starstarstarstarstar

FDA Drug Safety Podcasts

RSS Feed URL

Claim this podcast

Remove this podcast

Play Latest Episode:

Title: FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura

FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura

April 18th, 2019

FDA medical oncologists discuss the February 6, 2019, approval of caplacizumab-yhdp for acquired thrombotic thrombocytopenic purpura (aTTP), in combination… Go to Episode

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

March 12th, 2019

FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously… Go to Episode

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

December 13th, 2018

FDA medical oncologists discuss the Nov. 26, 2018, accelerated approval of larotrectinib for adult and pediatric patients. Go to Episode

FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia

November 29th, 2018

FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy… Go to Episode